-
Mashup Score: 1
Sacituzumab govitecan showed promising response and survival data in the extensive-stage small cell lung cancer cohort of the phase 2 TROPiCS-03 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices. #mmsm | @Rfonsi1 @HadidiSamer https://t.co/7S38KEoYYI https://t.co/L84VYVvCBD
-
-
Mashup Score: 6
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD. #kicsm | @kidneycan @LisaHenske https://t.co/9u0SZw74aN
-
-
Mashup Score: 0FDA Approves Remestemcel-L in Pediatric SR-aGVHD - 3 day(s) ago
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of rememstemcel-L in pediatric SR-aGVHD.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA approves remestemcel-L-rknd for pediatric patients with steroid-refractory acute GVHD. #hematology | @FDAOncology https://t.co/amwNeQJUh9 https://t.co/lsmpExo5S1
-
-
Mashup Score: 0
Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss recent clinical trial findings and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma. #mmsm | @End_myeloma @DrOlaLandgren @MMBaljevicMD https://t.co/kqTFzz5Qp3
-
-
Mashup Score: 1
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd. #mmsm | @myelomatips https://t.co/PNopNCMTOQ https://t.co/5ZCXrDnuJc
-
-
Mashup Score: 2FDA Approves Ensartinib in Metastatic ALK-Positive NSCLC - 4 day(s) ago
Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA approves ensartinib for patients with ALK-positive locally advanced or metastatic NSCLC. #NSCLC | @FDAOncology https://t.co/vIqmh3uyD8 https://t.co/pI63jQru6x
-
-
Mashup Score: 0
The phase 3 KeyVibe-003, KeyVibe-007, and KEYFORM-008 trials investigating vibostolimab and favezelimab have been discontinued.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Clinical development programs including the KeyVibe program investigating the anti–TIGIT antibody vibostolimab and the KEYFORM program investigating the anti–LAG-3 agent favezelimab have been discontinued. #NSCLC #lymsm https://t.co/DQakHmBNST https://t.co/MAYVE2cOZw
-
-
Mashup Score: 3
Results from the phase 3 AVA-PED-301 trial support the FDA decision for avatrombopag in pediatric thrombocytopenia.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The FDA has accepted a new drug application for avatrombopag as a treatment for pediatric patients 1 year or older with persistent or chronic immune thrombocytopenia who did not experience a response with prior therapy. #MedTwitter #oncology https://t.co/guRnVgMRWZ
-
-
Mashup Score: 1
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer. #bcsm #SABCS24 | @SABCSSanAntonio @hoperugo https://t.co/0sLjbNjx07
-
Sacituzumab govitecan has been granted the breakthrough therapy designation by the FDA for the treatment of adult patients who have ES-SCLC and have experienced disease progression on or following platinum-based chemotherapy. #lcsm https://t.co/60vRHeQAFI